Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Down 40.0% in May

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 65,085 shares, a decrease of 40.0% from the May 14th total of 108,418 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 44,667 shares, the days-to-cover ratio is presently 1.5 days.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings cut shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Up 1.9%

NASDAQ:DWTX traded up $0.03 during mid-day trading on Monday, reaching $1.57. 70,684 shares of the company were exchanged, compared to its average volume of 77,052. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50. The company has a fifty day moving average of $1.69 and a 200 day moving average of $3.03. The stock has a market cap of $52.80 million, a PE ratio of -0.15 and a beta of 1.70.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. On average, equities research analysts anticipate that Dogwood Therapeutics will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.